{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:15:56Z","timestamp":1780514156533,"version":"3.54.1"},"reference-count":66,"publisher":"Impact Journals, LLC","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,9,30]]},"DOI":"10.18632\/aging.203554","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T18:58:11Z","timestamp":1632855491000},"page":"22474-22489","source":"Crossref","is-referenced-by-count":4,"title":["Identification of genes and pathways leading to metastasis and poor prognosis in melanoma"],"prefix":"10.18632","volume":"13","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"},{"name":"Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"},{"name":"Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"},{"name":"Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"},{"name":"Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.critrevonc.2013.01.003","article-title":"Targeting BRAF in melanoma: biological and clinical challenges.","volume":"8","author":"Voit","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.phrs.2017.02.014","article-title":"Nanomedicine as a potent strategy in melanoma tumor microenvironment.","volume":"12","author":"Passirani","year":"2017","journal-title":"Pharmacol Res"},{"key":"3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma.","volume":"1","author":"Long","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/jso.25604","article-title":"Melanoma.","volume":"12","author":"Scoggins","year":"2019","journal-title":"J Surg Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaad.2011.06.047","article-title":"Molecular biology of melanoma.","volume":"6","author":"Maize","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejcsup.2013.07.011","article-title":"Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations.","volume":"1","author":"Dummer","year":"2013","journal-title":"EJC Suppl"},{"key":"7","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma.","volume":"16","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.","volume":"46","author":"Tsang","year":"2010","journal-title":"Nature"},{"key":"9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/1535-7163.MCT-15-0617","article-title":"A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.","volume":"1","author":"Kalkuhl","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.2147\/OTT.S75104","article-title":"Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma.","volume":"9","author":"Argenziano","year":"2016","journal-title":"Onco Targets Ther"},{"key":"11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","volume":"38","author":"Mauch","year":"2012","journal-title":"Lancet"},{"key":"12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.","volume":"3","author":"Kudchadkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1517\/14656566.2015.1044971","article-title":"BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.","volume":"1","author":"Larkin","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"14","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.","volume":"7","author":"Ribas","year":"2015","journal-title":"Sci Transl Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.31889","article-title":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.","volume":"12","author":"Shoushtari","year":"2019","journal-title":"Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"172621","DOI":"10.1016\/j.ejphar.2019.172621","article-title":"Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.","volume":"86","author":"Marchetti","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/CCO.0000000000000428","article-title":"Medical bioinformatics in melanoma.","volume":"3","author":"Cheng","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"18","unstructured":"Bleyer, O'Leary, Barr, Ries, (eds). Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006."},{"key":"19","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.","volume":"2","author":"Alaibac","year":"2014","journal-title":"In Vivo"},{"key":"20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","article-title":"Melanoma epidemiology, biology and prognosis.","volume":"1","author":"Larkin","year":"2013","journal-title":"EJC Suppl"},{"key":"21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11864-013-0228-6","article-title":"Metastatic melanoma to the brain: surgery and radiation is still the standard of care.","volume":"1","author":"Lim","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.prp.2015.05.010","article-title":"Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review.","volume":"21","author":"Lai","year":"2015","journal-title":"Pathol Res Pract"},{"key":"23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2017.08.052","article-title":"ABCB5 promotes melanoma metastasis through enhancing NF-\u03baB p65 protein stability.","volume":"49","author":"Liu","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.18632\/aging.101418","article-title":"KCNQ1OT1 promotes melanoma growth and metastasis.","volume":"1","author":"Tao","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/pcmr.12886","article-title":"CD147 regulates melanoma metastasis via the NFAT1-MMP-9 pathway.","volume":"3","author":"Peng","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/jid.2015.160","article-title":"Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.","volume":"13","author":"Ryu","year":"2015","journal-title":"J Invest Dermatol"},{"key":"27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR Signaling in Cancer.","volume":"4","author":"Mosca","year":"2014","journal-title":"Front Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"C281","DOI":"10.1152\/ajpcell.00422.2003","article-title":"G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K\/AKT\/mTOR\/p70S6K1 signaling in human ovarian cancer cells.","volume":"28","author":"Jiang","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"29","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: roles beyond cell cycle regulation.","volume":"14","author":"Kaldis","year":"2013","journal-title":"Development"},{"key":"30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3892\/or.2012.2208","article-title":"Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth.","volume":"2","author":"Yeh","year":"2013","journal-title":"Oncol Rep"},{"key":"31","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood-2010-06-288027","article-title":"Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors.","volume":"11","author":"Chen-Kiang","year":"2011","journal-title":"Blood"},{"key":"32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1023\/a:1023785332315","article-title":"Regulators of G1 cyclin-dependent kinases and cancers.","volume":"2","author":"Yang","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"33","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3892\/or.2012.2060","article-title":"Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1\/CIP1, in human breast cancer cells.","volume":"2","author":"Yoo","year":"2012","journal-title":"Oncol Rep"},{"key":"34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.bbrc.2020.04.043","article-title":"PLA2G10 facilitates the cell-cycle progression of soft tissue leiomyosarcoma cells at least by elevating cyclin E1\/CDK2 expression.","volume":"52","author":"Dong","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-17-0602","article-title":"Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.","volume":"1","author":"Blain","year":"2018","journal-title":"Mol Cancer Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs.","volume":"13","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1080\/15384101.2019.1667705","article-title":"Ganoderiol F purified from Ganoderma leucocontextum retards cell cycle progression by inhibiting CDK4\/CDK6.","volume":"1","author":"Yang","year":"2019","journal-title":"Cell Cycle"},{"key":"38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations.","volume":"13","author":"Escribano","year":"2007","journal-title":"Br J Haematol"},{"key":"39","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1158\/1078-0432.CCR-11-3028","article-title":"Inhibition of the Kit ligand\/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy.","volume":"1","author":"R\u00fcegg","year":"2012","journal-title":"Clin Cancer Res"},{"key":"40","first-page":"1064","article-title":"SCF\/c-KIT signaling promotes mucus secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma.","volume":"8","author":"Zhou","year":"2018","journal-title":"Am J Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00432-008-0447-6","article-title":"Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients.","volume":"13","author":"Mao","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2147\/DDDT.S89114","article-title":"Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.","volume":"1","author":"Ahmadipour","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12253-019-00788-w","article-title":"KIT Mutation Incidence and Pattern of Melanoma in Central Europe.","volume":"2","author":"T\u00edm\u00e1r","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"44","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/ajcp\/aqz209","article-title":"BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.","volume":"15","author":"Patrizi","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"45","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","article-title":"Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy.","volume":"1","author":"Panicot-Dubois","year":"2019","journal-title":"Front Immunol"},{"key":"46","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.26355\/eurrev_202003_20525","article-title":"Association of von Willebrand factor (vWF) expression with lymph node metastasis and hemodynamics in papillary thyroid carcinoma.","volume":"2","author":"Liu","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"47","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.jbo.2020.100325","article-title":"von Willebrand factor promotes platelet-induced metastasis of osteosarcoma through activation of the VWF-GPIb axis.","volume":"2","author":"Zhao","year":"2020","journal-title":"J Bone Oncol"},{"key":"48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41389-017-0023-5","article-title":"Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma.","volume":"7","author":"Li","year":"2018","journal-title":"Oncogenesis"},{"key":"49","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3748\/wjg.v11.i14.2166","article-title":"Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma.","volume":"1","author":"Chen","year":"2005","journal-title":"World J Gastroenterol"},{"key":"50","doi-asserted-by":"publisher","first-page":"e22219","DOI":"10.1002\/jcla.22219","article-title":"Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.","volume":"3","author":"Chen","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jprot.2014.04.021","article-title":"The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study.","volume":"10","author":"Ren","year":"2014","journal-title":"J Proteomics"},{"key":"52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-018-0659-4","article-title":"Novel antibodies against GPIb\u03b1 inhibit pulmonary metastasis by affecting vWF-GPIb\u03b1 interaction.","volume":"1","author":"Liang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"53","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s10552-013-0267-0","article-title":"Characteristics of patients diagnosed with both melanoma and renal cell cancer.","volume":"2","author":"Polascik","year":"2013","journal-title":"Cancer Causes Control"},{"key":"54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canep.2018.10.003","article-title":"Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.","volume":"5","author":"Kim","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.","volume":"1","author":"McMahon","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13543784.2019.1558442","article-title":"BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.","volume":"2","author":"Aiba","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"57","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/ijms21051723","article-title":"Regulatory Mechanism of MicroRNA Expression in Cancer.","volume":"2","author":"Song","year":"2020","journal-title":"Int J Mol Sci"},{"key":"58","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.3892\/ol.2018.8045","article-title":"MicroRNA-124-3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study.","volume":"1","author":"Ma","year":"2018","journal-title":"Oncol Lett"},{"key":"59","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/cdd.2010.164","article-title":"MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival.","volume":"1","author":"Westermann","year":"2011","journal-title":"Cell Death Differ"},{"key":"60","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.molonc.2015.03.013","article-title":"miRNA-221 and miRNA-222 induce apoptosis via the KIT\/AKT signalling pathway in gastrointestinal stromal tumours.","volume":"9","author":"Merkelbach-Bruse","year":"2015","journal-title":"Mol Oncol"},{"key":"61","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies.","volume":"4","author":"Smyth","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"62","article-title":"gplots: Various R programming tools for plotting data.","volume":"3","author":"Lodewijk","year":"2016","journal-title":"R package version"},{"key":"63","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters.","volume":"1","author":"He","year":"2012","journal-title":"OMICS"},{"key":"64","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","article-title":"ggplot2: elegant graphics for data analysis.","author":"Wickham","year":"2016","journal-title":"springer"},{"key":"65","first-page":"e24","article-title":"Package \u2018corrplot\u2019.","volume":"5","author":"Zemla","year":"2017","journal-title":"Statistician"},{"key":"66","doi-asserted-by":"publisher","first-page":"e82160","DOI":"10.1371\/journal.pone.0082160","article-title":"CyTargetLinker: a cytoscape app to integrate regulatory interactions in network analysis.","volume":"8","author":"Coort","year":"2013","journal-title":"PLoS One"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T15:47:27Z","timestamp":1633448847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":66,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,30]]}},"alternative-id":["203554","34582363"],"URL":"https:\/\/doi.org\/10.18632\/aging.203554","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}